



**MEK1 ELISA kit**  
**Catalog No. ADI-900-122A**  
**96 Well Kit**

**Table of Contents**

|                                   |      |    |
|-----------------------------------|------|----|
| Description                       | Page | 2  |
| Introduction                      |      | 2  |
| Precautions                       |      | 2  |
| Materials Supplied                |      | 3  |
| Storage                           |      | 3  |
| Materials Needed but Not Supplied |      | 3  |
| Sample Handling                   |      | 4  |
| Dilutional Linearity              |      | 4  |
| Procedural Notes                  |      | 5  |
| Reagent Preparation               |      | 5  |
| Assay Procedure                   |      | 6  |
| Calculation of Results            |      | 7  |
| Typical Results                   |      | 8  |
| Typical Standard Curve            |      | 8  |
| Performance Characteristics       |      | 9  |
| References                        |      | 11 |
| Limited Warranty                  |      | 12 |

**FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.**

## **Description**

The MEK1 ELISA kit is a complete kit for the quantitative determination of pan or total MEK1 in cell lysates. Please read the complete kit insert before performing this assay. The kit uses a monoclonal antibody to MEK1 immobilized on a microtiter plate to bind the MEK1 in the standards or samples. A recombinant phosphorylated MEK1 Standard is provided in the kit. After a short incubation the excess sample or standard is washed out and a rabbit polyclonal antibody to MEK1/2 is added. This antibody binds to the MEK1 captured on the plate. After a short incubation the excess antibody is washed out and anti-rabbit IgG conjugated to Horseradish peroxidase is added, which binds to the polyclonal MEK1/2 antibody. Excess conjugate is washed out and substrate is added. After a short incubation, the enzyme reaction is stopped and the color generated is read at 450 nm. The measured optical density is directly proportional to the concentration of MEK1 in either standards or samples. To measure phospho-MEK1, please refer to Catalog No. ADI-900-119. For further explanation of the principles and practices of immunoassays please see the excellent books by Chard<sup>1</sup> or Tijssen<sup>2</sup>.

## **Introduction**

MEK1 is also known by a variety of other names. They include dual specificity mitogen-activated protein kinase kinase (MAP kinase kinase 1 or MAPKK 1), ERK activator kinase 1, MAPK/ERK kinase 1, ERK kinase 1 and MAP kinase kinase. MEK1 is a 393 amino acid, 43.5kD protein that is highly conserved in evolution<sup>3</sup>. MEK phosphorylates threonine and tyrosine residues on MAP kinases ERK 1 and 2 (p44 and p42 MAP kinase)<sup>4</sup>. MEK participates in a wide range of cellular processes including cell proliferation<sup>5</sup>, differentiation<sup>6</sup> and apoptosis<sup>7</sup>. MEK1 is activated by phosphorylation of Ser<sup>218</sup> and Ser<sup>222</sup> by the serine-threonine kinase RAF1, which is part of the p21ras signal transduction pathway. Constitutive activation of MEK1 results in cellular transformation. This protein kinase has been reported to be a likely target for pharmacological intervention in proliferative diseases<sup>8</sup>. Recent literature reviews cover MEK activity in great detail<sup>9-10</sup>.

## **Precautions**

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

1. Stop Solution 2 is a 1N hydrochloric acid solution. This solution is caustic; care should be taken in use.
2. The activity of the Horseradish peroxidase conjugate is affected by nucleophiles such as azide, cyanide and hydroxylamine.
3. We test this kit's performance with a variety of buffers, however it is possible that high levels of interfering substances may cause variation in assay results.
4. The phospho-MEK1 Standard provided, Catalog No. 80-1137, should be handled with care because of the known and unknown effects of MEK.
5. The phospho-MEK1 Standard should be stored at or below -20 °C. Do not repeatedly freeze-thaw.

## **Materials Supplied**

- 1. MEK Microtiter Plate, One Plate of 96 Wells, Catalog No. 80-1115**  
A plate using break-apart strips coated with a mouse monoclonal antibody specific to MEK1.
- 2. Total MEK Antibody, 10 mL, Catalog No. 80-1135**  
A yellow solution of rabbit polyclonal antibody to Total MEK1 and 2.
- 3. Assay Buffer 21, 100 mL, Catalog No. 80-1519**  
Tris Buffer Saline containing proteins, detergents and phosphatase inhibitors.
- 4. Total MEK Conjugate, 10 mL, Catalog No. 80-1143**  
A blue solution of anti-rabbit IgG conjugated to Horseradish peroxidase.
- 5. Cell Lysis Buffer 3, 100 mL, Catalog No. 80-1134**  
100 mM Tris, pH 7.5, 2 mM EDTA, 2 mM EGTA, 5 mM  $\beta$ -glycerophosphate, 20 mM sodium pyrophosphate, 0.1% Triton X-100, 0.1% Tween 20 and 0.1% Hydorol M.
- 6. Wash Buffer Concentrate, 100 mL, Catalog No. 80-1287**  
Tris buffered saline containing detergents.
- 7. phospho-MEK1 Standards, 2 each, Catalog No. 80-1137**  
Two vials containing 5,000 pg each lyophilized recombinant human phospho-MEK1.
- 8. TMB Substrate, 10 mL, Catalog No. 80-0350**  
A solution of 3,3',5,5' tetramethylbenzidine (TMB) and hydrogen peroxide. **Protect from prolonged exposure to light.**
- 9. Stop Solution 2, 10 mL, Catalog No. 80-0377**  
A 1N solution of hydrochloric acid in water. Keep tightly capped. Caution: **Caustic.**
- 10. Total MEK1 Assay Layout Sheet, 1 each, Catalog No. 30-0196**
- 11. Plate Sealer, 3 each, Catalog No. 30-0012**

## **Storage**

All components of this kit, **except the Standard**, are stable at 4 °C until the kit's expiration date. The Standard **must** be stored at or below -20 °C.

## **Materials Needed but Not Supplied**

1. Deionized or distilled water.
2. Phenylmethanesulfonyl Fluoride (PMSF), Sigma #P7626 or equivalent.
3. Activated Sodium Orthovanadate, Sigma #S6508 or equivalent.
4. Protease Inhibitor Cocktail (PIC), Sigma #P8340 or equivalent.
5. Precision pipets for volumes between 100  $\mu$ L and 1,000  $\mu$ L.
6. Repeater pipet for dispensing 100  $\mu$ L.
7. Disposable beakers for diluting buffer concentrates.
8. Graduated cylinders.
9. A microplate shaker.
10. Adsorbent paper for blotting.
11. Microplate reader capable of reading at 450 nm.
12. Graph paper for plotting the standard curve, or preferably data reduction software capable of performing 4 parameter logistic curve fitting.

## **Sample Handling**

The MEK1 ELISA kit is compatible with MEK1 samples in a wide range of cell lysates. Samples diluted sufficiently into Assay Buffer 21 plus Inhibitors (see Reagent Preparation) can be read directly from a standard curve. It is recommended that all samples be lysed with the provided Cell Lysis Buffer 3 (equivalent to Assay Buffer 22 in phospho-MEK1 ELISA Kit) modified by the addition of PMSF and activated Sodium Orthovanadate (see Reagent Preparation) immediately prior to use. Samples lysed with Cell Lysis Buffer 3 plus Inhibitors require further dilution with Assay Buffer 21 plus Inhibitors prior to running the assay. A minimum 1:4 to 1:16 dilution is recommended to remove matrix interference in the assay. Due to differences in cell types, number of cells, or total cellular protein concentration, lysates may require greater dilution with the assay buffer to remove interference or to be read within the standard range.

**If the end user chooses to use another lysis buffer, the end-user must determine the appropriate dilution and assay validation.** Only standard curves generated in Assay Buffer 21 plus Inhibitors should be used to calculate the concentration of MEK1. Samples must be stored frozen at or below -70°C to avoid loss of bioactive MEK1. Excessive freeze/thaw cycles should be avoided. Prior to assay, frozen samples should be brought to 4°C slowly and gently mixed.

## **Dilutional Linearity**

The minimum required dilution for several common samples was determined by serially diluting samples into the assay buffer plus inhibitors and identifying the dilution at which linearity is observed. Jurkat lysates treated with PMA and DMSO were diluted in to the assay buffer plus inhibitors to produce values within the dynamic range of the assay.

| Dilution | Average % of Expected                          |   |
|----------|--|---|
|          | Jurkat Lysates treated with PMA 5M cells/0.5mL | Jurkat Lysates treated with DMSO 5M cells/0.5mL |
| 1:2      | 58%  | 51%   |
| 1:4      | 67%  | 58%   |
| 1:8      | 82%  | 68%   |
| 1:16     | 73%  | 76%   |
| 1:32     | 100%   | 89%   |
| 1:64     | ---  | 100%  |

## **Procedural Notes**

1. Do not mix components from different kit lots or use reagents beyond the kit expiration date.
2. Allow all reagents to warm to room temperature for at least 30 minutes before opening.
3. Standards must be made up in polypropylene tubes.
4. Pre-rinse the pipet tip with reagent, use fresh pipet tips for each sample, standard and reagent.
5. Pipet standards and samples to the bottom of the wells.
6. Add the reagents to the side of the well to avoid contamination.
7. This kit uses break-apart microtiter strips, which allow the user to measure as many samples as desired. Unused wells must be kept desiccated at 4 °C in the sealed bag. The wells should be used in the frame provided.
8. **Prior to addition of antibody, conjugate and substrate, ensure that there is no residual wash buffer in the wells. Any remaining wash buffer may cause variation in assay results.**

## **Reagent Preparation**

### **1. Wash Buffer**

Prepare the Wash Buffer by diluting 50 mL of the supplied concentrate with 950 mL of deionized water. This can be stored at room temperature until the kit expiration, or for 3 months, whichever is earlier.

### **2. Activated Sodium Orthovanadate**

Prepare a 200 mM solution of Sodium Orthovanadate using Sigma #S6508 or equivalent. Adjust the pH to 10.0 using either 1N NaOH or 1N HCl (at pH 10.0 the solution will be yellow). Boil the solution until it turns colorless (approximately 10 minutes). Cool the solution to room temperature. Readjust the pH to 10.0. Repeat the boiling and pH readjustment steps until the solution remains colorless and the pH stabilizes at 10.0. Aliquot and store the solution at -20 °C.

### **3. Cell Lysis Buffer 3 plus Inhibitors**

Allow to come to room temperature. Ensure Cell Lysis Buffer 3 is completely in solution prior to use. Immediately prior to cell lysis, PMSF and Activated Sodium Orthovanadate must be added to the buffer. Add PMSF, such as Sigma #P7626, to a final concentration of 1 mM. Add Activated Sodium Orthovanadate to a final concentration of 2 mM.

Do not add Protease Inhibitor Cocktail (PIC) to this buffer if the same lysates will be used in the phospho MEK1 ELISA kit (Catalog No. 900-119).

**Fresh Cell Lysis Buffer 3 plus Inhibitors must be made each time the cells are lysed.**

### **4. Assay Buffer 21 plus Inhibitors**

Immediately prior to use in the assay, PMSF and PIC must be added to the buffer. If using Sigma Protease Inhibitor Cocktail #P8340, add 0.5 µL/mL or equivalent concentration according to alternate vendor's specification sheet. Add PMSF, such as Sigma #P7626, to a final concentration of 1 mM.

**This modified Assay Buffer 21 must be used for standard reconstitution and all sample and standard dilutions to ensure optimal integrity of MEK1. Fresh Assay Buffer 21 plus Inhibitors must be made for each assay.**

## 5. phospho-MEK1 Standards

Allow the lyophilized phospho-MEK1 standard to warm to room temperature. Add 500  $\mu\text{L}$  of Assay Buffer 21 plus Inhibitors to the lyophilized phospho-MEK1 vial and vortex. Wait 5 minutes and vortex again prior to use. Label the vial standard #1. Label five 12x75 mm polypropylene tubes #2 through #6. Pipet 250  $\mu\text{L}$  of Assay Buffer 21 plus Inhibitors into tubes #2 through #6. Add 250  $\mu\text{L}$  of reconstituted standard to tube #2 and vortex. Add 250  $\mu\text{L}$  of tube #2 to tube #3 and vortex thoroughly. Continue this for tubes #4 through #6.

**The concentration of phospho-MEK1 in tubes #1 through #6 will be 10,000, 5,000, 2,500, 1,250, 625, and 312.5 pg/mL respectively. See Total MEK1 Assay Layout Sheet for dilution details.**

**Reconstituted and diluted standards should be used within 20 minutes of preparation.**

### Assay Procedure

**Bring all reagents to room temperature for at least 30 minutes prior to opening.**

**All standards, controls and samples should be run in duplicate.**

1. Refer to the Assay Layout Sheet to determine the number of wells to be used and put any remaining wells with the desiccant back into the pouch and seal the ziploc. Store unused wells at 4  $^{\circ}\text{C}$ .
2. Pipet 100  $\mu\text{L}$  of Assay Buffer 21 plus Inhibitors into the S0 (0 pg/mL standard) wells.
3. Pipet 100  $\mu\text{L}$  of Standards #1 through #6 into the appropriate wells.
4. Pipet 100  $\mu\text{L}$  of the Samples into the appropriate wells.
5. Tap the plate gently to mix the contents.
6. Seal the plate and incubate at room temperature on a plate shaker for 1 hour at  $\sim 500$  rpm.
7. Empty the contents of the wells and wash by adding 400  $\mu\text{L}$  of wash solution to every well. Repeat the wash 3 more times for a total of **4 washes**. After the final wash, empty or aspirate the wells and firmly tap the plate on a lint free paper towel to remove any remaining wash buffer.
8. Pipet 100  $\mu\text{L}$  of yellow Antibody into each well, except the Blank.
9. Seal the plate and incubate at room temperature on a plate shaker for 1 hour at  $\sim 500$  rpm.
10. Empty the contents of the wells and wash by adding 400  $\mu\text{L}$  of wash solution to every well. Repeat the wash 3 more times for a total of **4 washes**. After the final wash, empty or aspirate the wells and firmly tap the plate on a lint free paper towel to remove any remaining wash buffer.
11. Add 100  $\mu\text{L}$  of blue Conjugate to each well, except the Blank.
12. Seal the plate and incubate at room temperature on a plate shaker for 30 minutes at  $\sim 500$  rpm.
13. Empty the contents of the wells and wash by adding 400  $\mu\text{L}$  of wash solution to every well. Repeat the wash 3 more times for a total of **4 washes**. After the final wash, empty or aspirate the wells and firmly tap the plate on a lint free paper towel to remove any remaining wash buffer.
14. Pipet 100  $\mu\text{L}$  of Substrate Solution into each well.
15. Incubate for 30 minutes at room temperature on a plate shaker at  $\sim 500$  rpm.
16. Pipet 100  $\mu\text{L}$  Stop Solution 2 to each well. This stops the reaction and the plate should be read immediately.
17. Blank the plate reader against the Blank wells, read the optical density at 450 nm. If the plate reader is not able to be blanked against the Blank wells, manually subtract the mean optical density of the Blank wells from all the readings.

### **Calculation of Results**

Several options are available for the calculation of the concentration of MEK1 in the samples. We recommend that the data be handled by an immunoassay software package utilizing a 4 parameter logistic curve fitting program. If data reduction software is not readily available, the concentration of MEK1 can be calculated as follows:

1. Calculate the average net Optical Density (OD) bound for each standard and sample by subtracting the average Blank OD from the average OD for each standard and sample.

$$\text{Average Net OD} = \text{Average OD} - \text{Average Blank OD}$$

2. Using linear graph paper, plot the Average Net OD for each standard versus MEK1 concentration in each standard. Approximate a straight line through the points. The concentration of MEK1 in the unknowns can be determined by interpolation.


## **Typical Results**

The results shown below are for illustration only and **should not** be used to calculate results from another assay.

| <u>Sample</u> | <u>Average OD</u> | <u>Net OD</u> | <u>MEK1<br/>(pg/mL)</u> |
|---------------|-------------------|---------------|-------------------------|
| Blank         | 0.042             |               |                         |
| S0            | 0.278             | 0.236         | <b>0</b>                |
| S1            | 2.403             | 2.361         | <b>10,000</b>           |
| S2            | 1.387             | 1.345         | <b>5,000</b>            |
| S3            | 0.876             | 0.834         | <b>2,500</b>            |
| S4            | 0.577             | 0.535         | <b>1,250</b>            |
| S5            | 0.448             | 0.406         | <b>625</b>              |
| S6            | 0.365             | 0.323         | <b>312.5</b>            |
| Unknown #1    | 0.603             | 0.561         | <b>1,341</b>            |
| Unknown #2    | 0.390             | 0.348         | <b>445</b>              |

## **Typical Standard Curve**

A typical standard curve is shown below. This curve **must not** be used to calculate MEK1 concentrations; each user must run a standard curve for each assay.





## **Performance Characteristics**

The following parameters for this kit were determined using the guidelines listed in the National Committee for Clinical Laboratory Standards (NCCLS) Evaluation Protocols<sup>12</sup>.

### **Sensitivity**

Sensitivity of the assay, defined as the concentration of Total MEK measured at 2 standard deviations from the mean of 20 zeros along the standard curve, was determined to be 139.0 pg/mL.

### **Precision**

Intra-assay precision was determined by taking by assaying 20 replicates of three buffer controls containing Total MEK in a single assay.

| <b>pg/mL</b> | <b>%CV</b> |
|--------------|------------|
| 1477         | 5.4        |
| 779          | 5.6        |
| 385          | 15.7       |

**Inter-assay precision** was determined by measuring buffer controls (n=20) of varying Total MEK concentrations in multiple assays over several days.

| <b>pg/mL</b> | <b>%CV</b> |
|--------------|------------|
| 1457         | 6.1        |
| 796          | 11.9       |
| 432          | 5.9        |


### **Cross Reactivities.**

The cross reactivities for a number of related compounds were determined by dissolving the cross reactant in the kit assay buffer. These samples were then measured in the Total MEK1 assay and measured MEK1 concentration calculated. The % cross reactivity was calculated by comparison with the actual concentration of cross reactant in the sample and expressed as a percentage.

| <u>Compound</u> | <u>Cross Reactivity</u> |
|-----------------|-------------------------|
| pMEK1           | 91.0%                   |
| pMEK2           | 17.4%                   |
| pJNK            | 5.7%                    |
| ERK2            | 0.4%                    |
| GSK-3 $\beta$   | 0.1%                    |
| p38             | 0.1%                    |

## Parallelism

A parallelism experiment was carried out to determine if the recombinant MEK standard accurately measures MEK concentrations in biological matrices. To assess parallelism, values for Jurkat lysates were obtained from standard curve using four parameter logistic curve fitting. The obtained concentrations were plotted against the dilution factor. Parallelism indicates antibody-binding characteristics of the native and standard proteins are similar, allowing accurate determination of analyte.



## Spike and Recoveries

After diluting each sample matrix to its minimum required dilution, recombinant Total MEK1 was spiked at high, medium, and low concentrations. The recovery of the standard in spiked samples was compared to the recovery of identical spikes in the assay buffer. The mean and range of percent at three concentrations are indicated below for each matrix.

| Sample matrix                    | MRD | No. of Unique Samples | Spike Concentration (pg/mL) | Recovery of Spike |
|----------------------------------|-----|-----------------------|-----------------------------|-------------------|
| Jurkat Lysates treated with PMA  | 1:4 | 1                     | 7000                        | 103%              |
|                                  |     |                       | 1700                        | 99%               |
|                                  |     |                       | 400                         | 121%              |
| Jurkat Lysates treated with PMA  | 1:8 | 1                     | 7000                        | 104%              |
|                                  |     |                       | 1700                        | 100%              |
|                                  |     |                       | 400                         | 98%               |
| Jurkat Lysates treated with DMSO | 1:4 | 1                     | 7000                        | 83%               |
|                                  |     |                       | 1700                        | 84%               |
|                                  |     |                       | 400                         | 104%              |
| Jurkat Lysates treated with DMSO | 1:8 | 1                     | 7000                        | 90%               |
|                                  |     |                       | 1700                        | 86%               |
|                                  |     |                       | 400                         | 117%              |

## References

1. T. Chard, "An Introduction to Radioimmunoassay & Related Techniques 4th Ed.", (1990) Amsterdam: Elsevier.
2. P. Tijssen, "Practice & Theory of Enzyme Immunoassays", (1985) Amsterdam: Elsevier.
3. C.M. Crews, et al., Science, (1992) 258:478-480.
4. G. Hardie and S. Hanks, "The Protein Kinase Fact Book, Protein-Serine Kinases", (1995) San Diego, CA: Academic Press. 418.
5. C.C. Lin, et al., Cell Signal, (2002) 14(3):265-75.
6. M.B. Miranda, et al., Leukemia, (2002) 16(4):683-92.
7. H. Lin, et al., Exp. Cell Res., (2002) 272(2):192-8.
8. J.S. Sebolt-Leopold, et al., Nat. Med., (1999) 5(7):192-8.
9. J.T. Lee, et al., Leukemia, (2002) 16(4):485-507.
10. C. Peyssonnaud and A. Eychene, Biol. Cell, (2001) 93(1-2):53-62.
11. T.W. Schulte, et al., Mol. Cel. Biol., (1996) 16(10):5839-45.
12. National Committee for Clinical Laboratory Standards Evaluation Protocols, SC1, (1989) Villanova, PA: NCCLS.



#### **USE FOR RESEARCH PURPOSES ONLY**

Unless otherwise specified expressly on the packaging, all products sold hereunder are intended for and may be used for research purposes only and may not be used for food, drug, cosmetic or household use or for the diagnosis or treatment of human beings. Purchase does not include any right or license to use, develop or otherwise exploit these products commercially. Any commercial use, development or exploitation of these products or development using these products without the express written authorization of Enzo Life Sciences, Inc. is strictly prohibited. Buyer assumes all risk and liability for the use and/or results obtained by the use of the products covered by this invoice whether used singularly or in combination with other products.

#### **LIMITED WARRANTY; DISCLAIMER OF WARRANTIES**

These products are offered under a limited warranty. The products are guaranteed to meet all appropriate specifications described in the package insert at the time of shipment. Enzo Life Sciences' sole obligation is to replace the product to the extent of the purchasing price. All claims must be made to Enzo Life Sciences, Inc., within five (5) days of receipt of order. THIS WARRANTY IS EXPRESSLY IN LIEU OF ANY OTHER WARRANTIES OR LIABILITIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT OF THE PATENT OR OTHER INTELLECTUAL PROPERTY RIGHTS OF OTHERS, AND ALL SUCH WARRANTIES (AND ANY OTHER WARRANTIES IMPLIED BY LAW) ARE EXPRESSLY DISCLAIMED.

#### **TRADEMARKS AND PATENTS**

Several Enzo Life Sciences products and product applications are covered by US and foreign patents and patents pending.

**[www.enzolifesciences.com](http://www.enzolifesciences.com)**  
***Enabling Discovery in Life Science***<sup>®</sup>

#### **Global Headquarters**

##### **Enzo Life Sciences Inc.**

10 Executive Blvd  
Farmingdale, NY 11735  
(p) 1-800-942-0430  
(f) 1-631-694-7501  
(e) [info-usa@enzolifesciences.com](mailto:info-usa@enzolifesciences.com)

##### **Enzo Life Sciences (ELS) AG**

Industriestrasse 17, Postfach  
CH-4415 Lause / Switzerland  
(p) +41/0 61 926 89 89  
(f) +41/0 61 926 89 79  
(e) [info-ch@enzolifesciences.com](mailto:info-ch@enzolifesciences.com)

Please visit our website at [www.enzolifesciences.com](http://www.enzolifesciences.com) for additional contact information.